12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ublituximab: Phase I/II data

Data from the Phase I portion of an open-label, North American Phase I/II trial showed that IV ublituximab plus oral Revlimid lenalidomide led to rapid lymphocyte depletion in 4 of 5 evaluable patients. No dose-limiting toxicities (DLTs) have been observed. The dose-escalation Phase I portion is evaluating 450, 600 and 900 mg ublituximab on days 1, 8 and 15 for 2 cycles followed by...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >